Niveauet for serobeskyttelse mod hepatitis B efter administration af Twinrix Voksen var 92% og 87, 5% efter henholdsvis 7 og 12 måneder, mens det var 80% og 74% med GlaxoSmithKline Biologicals monovalente 20 µg hepatitis B- vaccine og 71% og 56% med en anden registreret monovalent 10 µg hepatitis- vaccine.
The seroprotection rate against hepatitis B after the administration of Twinrix Adult was 92% and 87.5% at 7 and 12 months respectively, versus 80% and 74% after the GlaxoSmithKline Biologicals monovalent 20µg hepatitis B vaccine, and 71% and 56% after another licensed monovalent 10µg hepatitis B vaccine.